

An independent review group appointed by CDC will evaluate each application (separately reviewing Project A—SARS and Project B—Hepatitis) against the following criteria:

1. Operational Plan (60 points)

a. Extent to which applicant presents an operational plan for initiating and conducting the project, which clearly and appropriately addresses all Recipient Activities in the application.

b. Extent to which applicant clearly identifies specific assigned responsibilities of all key professional personnel.

c. Extent to which the plan clearly describes the applicant's technical approach and method for conducting the proposed project and the extent to which the plan is adequate to accomplish the objectives.

d. Extent to which the applicant proposes specific draft study protocols or plans for the development of study protocols that are appropriate for achieving project objectives.

e. Extent to which the applicant describes plans for collaboration with CDC in initiating the project, developing final protocols, and ongoing operation of the project.

f. Extent to which the applicant describes how they will integrate the project(s) with related projects currently being conducted by the EIPs (such as with Unexplained Deaths and Critical Illnesses projects).

g. Does the application adequately address the CDC Policy requirements regarding the inclusion of women, ethnic, and racial groups in the proposed research. This includes: (1) The proposed plan for the inclusion of both sexes and racial and ethnic minority populations for appropriate representation; (2) The proposed justification when representation is limited or absent; (3) A statement as to whether the design of the study is adequate to measure differences when warranted; and (4) A statement as to whether the plans for recruitment and outreach for study participants include the process of establishing partnerships with communities and recognition of mutual benefits.

2. Description of Capacity (15 points)

a. Extent to which applicant demonstrates past experience in conducting activities similar to those proposed and that the new activities will complement current ones. Applicants that are already engaged in the Unexplained Deaths and Critical Illnesses project should demonstrate that Surveillance for SARS and Severe

Pneumonia Syndrome activities will be integrated with ongoing activities.

b. Extent to which applicant provides evidence that this activity can be accomplished while satisfactorily maintaining their ongoing EIP activities.

Extent to which applicant documents accomplishments in conducting active surveillance, applied epidemiologic research, laboratory research, and prevention research.

c. Extent to which applicant identifies key personnel with appropriate experience for the project.

Extent to which applicant includes letters of support from proposed collaborators indicating essential collaborating organizations or individuals and their willingness to participate as proposed. Do not include letters of support from CDC personnel.

3. Background (10 points)

a. Extent to which applicant demonstrates a clear understanding of the subject area, particularly as it relates to the local situation.

b. Extent to which applicant illustrates and justifies the need for the proposed project and demonstrates how the project is consistent with the purpose and objectives of the EIP and of this cooperative agreement supplement.

4. Evaluation (10 points)

Extent to which applicant provides a detailed and adequate plan for evaluating progress toward achieving project process and outcome objectives.

5. Measures of Effectiveness (5 points)

Does the applicant provide Measures of Effectiveness that will demonstrate the accomplishment of the various identified objectives of the grant? Are the measures objective/quantitative and do they adequately measure the intended outcome?

6. Budget (not scored)

Extent to which the proposed budget is reasonable, clearly justified, and consistent with the intended use of the cooperative agreement funds.

7. Human Subjects (not scored)

Does the application adequately address the requirements of Title 45 CFR part 46 for the protection of human subjects?

I. Other Requirements

Technical Reporting Requirements

Technical reporting requirements are the same as those under grantee's existing EIP cooperative agreement award.

The following additional requirements are applicable to this

program. For a complete description of each, see Appendix 3 of the program announcement as posted on the CDC Web site.

AR-1 Human Subjects Requirements

AR-2 Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research

AR-7 Executive Order 12372 Review

AR-10 Smoke-Free Workplace Requirements

AR-11 Healthy People 2010

AR-12 Lobbying Restrictions

J. Where To Obtain Additional Information

This and other CDC announcements, the necessary applications, and associated forms can be found on the CDC Web site, Internet address: <http://www.cdc.gov>.

Click on "Funding" then "Grants and Cooperative Agreements."

For general questions about this announcement, contact:

Technical Information Management,
CDC Procurement and Grants Office,
2920 Brandywine Road, Atlanta, GA
30341-4146, Telephone: 770-488-2700.

For business management and budget assistance, contact:

Lynn Walling, Grants Management Specialist, CDC Procurement and Grants Office, 2920 Brandywine Road, Atlanta, GA 30341-4146, e-mail address: Lwalling@cdc.gov.

For program technical assistance, contact:

Cathy Rebmann, National Center for Infectious Diseases (NCID), Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd., NE, Mailstop D-59, Atlanta, GA 30333, Telephone (404) 371-5363, e-mail address: csr9@cdc.gov.

or

Angela Slaughter, National Center for Infectious Diseases (NCID), Centers for Disease Control and Prevention (CDC), 1600 Clifton Rd., NE, Mailstop D-59, Atlanta, GA 30333, Telephone (404) 371-5357, e-mail address: aslaughter@cdc.gov.

Dated: July 9, 2003.

Sandra R. Manning,

*Director, Procurement and Grants Office,
Center for Disease Control and Prevention.*

[FR Doc. 03-17805 Filed 7-14-03; 8:45 am]

BILLING CODE 4163-18-P